Sanofi Is First To File Biosimilar Insulin Aspart

 
• By Ian Schofield

The European Medicines Agency is evaluating Sanofi's SAR341402, the first biosimilar insulin aspart product to be submitted for EU marketing authorization. If approved, the product will compete with Novo Nordisk's diabetes drug Novorapid/NovoLog.

Diabetes
The EMA is assessing the first biosimilar insulin aspart for diabetes • Source: Shutterstock

More from Biosimilars

More from Products